Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Dexcom

DexCom, GE, SLB: Why Experts Rate These Stocks at Strong Buy

Wall Street gives these three diverse names Strong Buy recommendations with high potential upside.

Kiplinger

DexCom Stock: Analyst Estimates & Ratings

Despite DexCom’s underwhelming price action, Wall Street analysts appear highly optimistic about its prospects.

Barchart

What You Need to Know Ahead of DexCom’s Earnings Release

DexCom is all geared up to announce its second-quarter earnings towards the end of this month, and analysts anticipate a single-digit bottom-line growth.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

2 ‘Strong Buy’ Stocks That the MAHA Movement AND Wall Street Love

Policies associated with the MAHA movement could boost these two stocks significantly.

Barchart

Diabetics at Risk: FDA Issues Highest-Level Recall on 2M Dexcom Devices Over 'Deadly Fault'

The FDA has recalled 2 million Dexcom glucose monitors due to a serious safety risk. Learn how diabetic patients should act immediately to protect their health.

International Business Times UK

DexCom Stock: Is DXCM Underperforming the Health Care Sector?

DexCom has underperformed the Health Care sector over the past year, but analysts are highly optimistic about the stock’s prospects.

Barchart

Garmin has patented long-term blood glucose tracking; here's how it'd work

Garmin watches already pair with Dexcom for indirect blood glucose monitoring. This patent shows how Garmin watches could directly help diabetics.

Android Central

Read news from The Economist, FT, and more,
with one subscription

Do Wall Street Analysts Like DexCom Stock?

Despite trailing the broader market over the past year, DexCom continues to attract strong optimism from Wall Street analysts, who maintain a highly positive outlook on the stock's long-term potential.

Barchart

DexCom Stock: Earnings Beat and New Market Access Drive Bull Case

Dexcom's strong quarterly performance and innovative product pipeline signal continued leadership and expansion within the evolving diabetes technology market.

MarketBeat

Oura brings AI-powered meals and glucose tracking to the US

Oura launches two metabolic features within the Oura app that help users track their meals, rise in glucose levels to manage their eating habits.

Android Central

Is DexCom Stock Underperforming the Dow?

DexCom significantly underperformed the Dow over the past year, yet analysts remain strongly bullish on the stock’s long term prospects.

Barchart

DexCom Stock Outlook: Is Wall Street Bullish or Bearish?

Although DexCom has significantly lagged behind the broader market over the past year, Wall Street analysts remain strongly optimistic about the stock's prospects.

Barchart

What to Expect From DexCom's Q4 2024 Earnings Report

DexCom is gearing up to release its fourth-quarter earnings next month, and analysts forecast single-digit profit growth.

Barchart

The Oura Ring is about giving your body a voice, says Oura CEO

The Oura Ring 4 set a standard in the smart ring industry, and its CEO is excited for the future to make Oura the ring connected to our health.

Android Central

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Is DexCom Stock Underperforming the Nasdaq?

Despite DexCom's lagging performance relative to the Nasdaq Composite over the past year, Wall Street analysts maintain a strong bullish outlook on the stock's prospects.

Benzinga

Key Takeaways From DexCom Analyst Ratings

DexCom (NASDAQ:DXCM) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.

TechRadar

The Stelo glucose biosensor changed the way I manage my diabetes - I tested it for two weeks, and here's how it went

The Stelo glucose biosensor is more affordable and accessible, but how well does it work for diabetics?

International Business Times

Dexcom Glucose Data To Be Integrated With ŌURA Rings

Dexcom and ŌURA have partnered to integrate Dexcom's glucose biosensing feature with the ŌURA Ring's health metrics to help improve consumers' metabolic health.

Get all your
news in one place.

100's of premium titles.
One news app.

TechRadar

Your Oura Ring will be able to show you glucose readings in 2025 – thanks to Dexcom integration

The company is now valued at over $5 billion

Barchart

Are Wall Street Analysts Predicting DexCom Stock Will Climb or Sink?

Despite DexCom’s underperformance relative to the broader market over the past year, Wall Street analysts remain bullish about the stock’s prospects.

Evening Standard

Nick Jonas wants to 'take bigger risks' as he reflects on 'wild' Jonas Brothers milestone

EXCLUSIVE The singer-songwriter and actor has crammed a lot into his 32 years of life and the ‘incredibly ambitious and driven’ star is determined there will be a lot more to come

The Conversation

Glucose monitors for diabetes have finally been funded – but a chronic workforce shortage will limit the benefits

Pharmac’s decision to fund continuous glucose monitors and automated insulin delivery systems for the approximately 18,000 people who currently live with type 1 diabetes in Aotearoa New Zealand is good news.

Barchart

Here's What to Expect From DexCom's Next Earnings Report

DexCom is poised to announce its third-quarter results later this month, with analysts predicting a double-digit decline in the company's earnings.

Barchart

Is DexCom Stock Underperforming the S&P 500?

Despite DexCom’s underperformance compared to the S&P 500 Index over the past year, Wall Street analysts are highly bullish about the stock’s prospects.

The Conversation

Ozempic, Wegovy, Rybelsus: Are we losing sight of overall health? Here’s what the science says

The craze for new drugs in the GLP-1 (Glucagon-like peptide 1) and GIP (Gastric inhibitory polypeptide) analogue class, better known under the trade names Ozempic and Wegovy, is remarkable, but it’s not totally unprecedented in the history of pharmaceutical blockbusters.

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.